University of Cambridge PhD Studentship in Cancer Biology 2027
Description
A fully-funded PhD studentship at the Cancer Research UK Cambridge Institute, University of Cambridge, investigating mechanisms…
Full Description
Pancreatic ductal adenocarcinoma (PDAC) remains a formidable clinical challenge. A major recent advance has been the development of KRAS inhibitors, which have shown considerable promise in clinical trials (1). For decades, KRAS was considered undruggable; however, these new inhibitors represent a potential turning point for patients with PDAC. Despite this progress, rapid therapy resistance has already been observed in both patients and pre-clinical mouse models, highlighting the urgent need to define the mechanisms that drive resistance and to identify rational combination therapies.
In our laboratory, we have established and validated a panel of genetically heterogeneous PDAC models. These studies have shown that malignant-cell genetics shape distinct, therapeutically actionable vulnerabilities through both cell-intrinsic programmes and changes in the surrounding tumor microenvironment [(2) and unpublished]. These observations create an important opportunity: we hypothesise that malignant stromal crosstalk within defined genetic contexts drives distinct mechanisms of resistance to KRAS inhibition. In support of this, our work indicates that cancer-associated fibroblasts play diverse roles in PDAC progression and activate pathways that may contribute to therapy resistance (3, 4). This PhD project will therefore identify malignant cell-intrinsic and malignant cell-extrinsic mechanisms of resistance to KRAS inhibition, including fibroblast-mediated mechanisms, across genetically distinct PDACs. We will prioritise PDAC genotypes for which we already have preliminary data suggesting candidate mechanisms of resistance.
The project will combine complementary models and techniques, including co-transplantation of organoids in mouse models, in vivo CRISPR, single-cell RNA sequencing, flow cytometry, multiplex immunofluorescence, spatial transcriptomics, and standard molecular biology approaches. A computational component may also be available, depending on the skills and interests of the student. Together, these strategies will define how intra-tumor genetic heterogeneity influences response and resistance to KRAS inhibition, complementing ongoing studies in the laboratory investigating inter-tumor genetic heterogeneity.
Summary
- Application Deadline: October 16, 2026
- Study Level: PhD
- Sponsor: University of Cambridge
- City to Study: Cambridge
- School to Study: University of Cambridge
- Course to Study: Biology, Cancer Studies
- Eligible Country: All Countries
Funding Types
Apply
Application LinkDeadline
Oct 16, 2026
This scholarship has expired
Benefits
- Fully-funded PhD studentship (stated as fully-funded in the listing).
- Project combines in vivo models, organoids, in vivo CRISPR, single-cell RNA sequencing, flow cytometry, multiplex immunofluorescence, spatial transcriptomics, and molecular biology approaches.
- Computational component may be available depending on student skills and interests.
How to Apply
Please apply via the University Applicant Portal at https://www.postgraduate.study.cam.ac.uk/courses/directory/cvcrpdmsc
You should select to commence study in October 2027.
Please quote reference SW51012 on your application and in any correspondence about this vacancy.
The University actively supports equality, diversity and inclusion and encourages applications from all sections of society.
The University has a responsibility to ensure that all employees are eligible to live and work in the UK.
For more information, visit University of Cambridge scholarship webpage.
Eligibility Criteria
- We welcome applications from both UK and overseas students.